This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic psychedelic

Our results indicate health and wellness motives and perceived mental health benefits among microdosers

Individualized dose escalation of 5-MeO-DMT may be preferable over single dose administration for clinical applications that aim to elicit a strong therapeutic response.

Our findings hold implications for the potential use of psychedelics for treating interpersonal elements of personality pathology as well as loneliness.

A model to support MDMA-assisted couple therapy is introduced, and future directions, including implications for intervention development and delivery, will be elucidated."

This review aims to discuss how psychedelics can promote and intensify psychotherapeutic key processes.

the potential use of psilocybin and perhaps similar compounds in the treatment of OCD and related conditions. Our experience with incidental observation, prospective research, and current explorations of psilocybin in OCD are also described.

Across a range of psychedelic substances and doses, reported pain scores improved substantially during and after psychedelic experiences.

“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,”

Escitalopram pretreatment significantly reduced bad drug effects, anxiety, other adverse effects of psilocybin compared with placebo pretreatment.

Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use.

A narrative review that integrates research on etiology and maintenance of social anxiety disorder and mechanisms of action of MDMA to examine how MDMA may enhance psychotherapy outcomes.

Findings highlight the challenges that Schedule 1 researchers are currently facing and suggest that the government should commission an urgent review

Ego death can be among the most transcendent or terrifying events of a person's life. But what exactly is happening in the brain during this kind of psychedelic experience?

Margaret Ross decided to move into researching alternatives for her oncology patients who were terrified of dying and experiencing existential distress in the face of their diagnosis.

The authors anticipate potential difficulties to broader health service implementation, and emphasise that creative responses to address them, will be important to avoid roadblocks in the future and keep the “psychedelic renaissance” on track.

Here is an interesting part of the scientific discussion triggered by the immensely successful MAPS study on MDMA-assisted therapy for PTSD.

This study examined data from 6,381 individuals reporting past-year hallucinogen use.

This study found that LSD affects the stream of thought within several levels (active, passive), facets (chaos, meaning, sensation, abstractness) and time points (from +2 h to +6 h). Increased chaos, meaning and abstract flow at +4 h indicate the utility of a late therapeutic window in psycholytic therapy.